Intramyocardial Injection of Autologous Bone Marrow-Derived Ex Vivo Expanded Mesenchymal Stem Cells in Acute Myocardial Infarction Patients is Feasible and Safe up to 5 Years of Follow-up

Autor: Saskia L.M.A. Beeres, Jan van Ramshorst, Matthijs A. Velders, Suzanne C. Cannegieter, Willem E. Fibbe, Imad Al Younis, Helèn Boden, Jeroen J. Bax, Douwe E. Atsma, Petra Dibbets-Schneider, Martin J. Schalij, Helene Roelofs, Sander F. Rodrigo, Jaap Jan Zwaginga, Georgette E. Hoogslag
Jazyk: angličtina
Rok vydání: 2013
Předmět:
Male
medicine.medical_specialty
Time Factors
medicine.medical_treatment
Myocardial Infarction
Pharmaceutical Science
Cell Separation
Kaplan-Meier Estimate
Mesenchymal Stem Cell Transplantation
Transplantation
Autologous
Disease-Free Survival
Ventricular Function
Left
Article
Injections
Neovascularization
Percutaneous Coronary Intervention
Clinical stem cell therapy
Acute myocardial infarction patients
Internal medicine
Genetics
medicine
Humans
Genetics(clinical)
Myocardial infarction
Adverse effect
Cells
Cultured
Genetics (clinical)
Aged
Cell Proliferation
Intramyocardial injection
business.industry
Mesenchymal stem cell
Percutaneous coronary intervention
Recovery of Function
Middle Aged
Autologous bone
medicine.disease
Transplantation
Treatment Outcome
Cardiology
Feasibility Studies
Molecular Medicine
Mesenchymal stem cells
Female
medicine.symptom
Cardiology and Cardiovascular Medicine
business
Ex vivo
Zdroj: Journal of Cardiovascular Translational Research, 6(5), 816-825
Journal of Cardiovascular Translational Research
Popis: In experimental studies, mesenchymal stem cell (MSC) transplantation in acute myocardial infarction (AMI) models has been associated with enhanced neovascularization and myogenesis. Clinical data however, are scarce. Therefore, the present study evaluates the safety and feasibility of intramyocardial MSC injection in nine patients, shortly after AMI during short-term and 5-year follow-up. Periprocedural safety analysis demonstrated one transient ischemic attack. No other adverse events related to MSC treatment were observed during 5-year follow-up. Clinical events were compared to a nonrandomized control group comprising 45 matched controls. A 5-year event-free survival after MSC-treatment was comparable to controls (89 vs. 91 %, P = 0.87). Echocardiographic imaging for evaluation of left ventricular function demonstrated improvements up to 5 years after MSC treatment. These findings were not significantly different when compared to controls. The present safety and feasibility study suggest that intramyocardial injection of MSC in patients shortly after AMI is feasible and safe up to 5-year follow-up.
Databáze: OpenAIRE
Externí odkaz: